A controlled trial of colchicine in primary biliary cirrhosis
| Autor: | Linda P. Hunt, Philip J. Johnson, Frank I. Lee, Nagib Y. Haboubi, Alexander Smith, Thomas W. Warnes |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
medicine.medical_specialty
Hepatology biology business.industry Bilirubin Biliary cirrhosis Serum albumin Albumin medicine.disease Placebo Gastroenterology Surgery chemistry.chemical_compound Primary biliary cirrhosis chemistry Internal medicine biology.protein Medicine Colchicine Liver function business |
| Zdroj: | Journal of Hepatology. 5:1-7 |
| ISSN: | 0168-8278 |
| DOI: | 10.1016/s0168-8278(87)80053-3 |
| Popis: | Colchicine (1 mg/day), or an identical placebo, was given to 64 patients with primary biliary cirrhosis in a double-blind controlled trial. Due to a novel, pair-matched trial design, the two groups were exceptionally well matched at entry. In comparison with placebo, colchicine produced a beneficial effect on serum albumin and bilirubin levels at 3 months in patients who had abnormal liver function (bilirubin greater than 20 mumol/l) at entry: (albumin, P = 0.047; bilirubin, P = 0.022). In patients with normal liver function at entry (bilirubin less than 20 mumol/l), beneficial effects were noted on total globulin levels at 3 months (P = 0.013) and on immunoglobulin G levels at 3 and 6 months (P = 0.044 and 0.001, respectively). At 18 months, survival estimate in the colchicine and placebo groups were 84% and 69%, respectively. The difference did not reach significance. Colchicine produced an early improvement in liver function and immunoglobulin levels. Few serious side effects were encountered, and colchicine clearly merits long-term study in the treatment of primary biliary cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|